238 related articles for article (PubMed ID: 30954620)
1. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
Park JE; Park J; Jun Y; Oh Y; Ryoo G; Jeong YS; Gadalla HH; Min JS; Jo JH; Song MG; Kang KW; Bae SK; Yeo Y; Lee W
J Control Release; 2019 May; 302():148-159. PubMed ID: 30954620
[TBL] [Abstract][Full Text] [Related]
2. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W
PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121
[TBL] [Abstract][Full Text] [Related]
3. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
[TBL] [Abstract][Full Text] [Related]
4. Size optimization of carfilzomib nanocrystals for systemic delivery to solid tumors.
Gadalla HH; Lee S; Kim H; Armstrong AT; Fathalla D; Habib F; Jeong H; Lee W; Yeo Y
J Control Release; 2022 Dec; 352():637-651. PubMed ID: 36349616
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model.
Jun Y; Xu J; Kim H; Park JE; Jeong YS; Min JS; Yoon N; Choi JY; Yoo J; Bae SK; Chung SJ; Yeo Y; Lee W
J Pharm Sci; 2020 Apr; 109(4):1615-1622. PubMed ID: 31945310
[TBL] [Abstract][Full Text] [Related]
6. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
[TBL] [Abstract][Full Text] [Related]
7. Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity.
Reichel D; Lee MJ; Lee W; Kim KB; Bae Y
Ther Deliv; 2016 Oct; 7(10):665-681. PubMed ID: 27790952
[TBL] [Abstract][Full Text] [Related]
8. Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity.
Taha MS; Cresswell GM; Park J; Lee W; Ratliff TL; Yeo Y
Nano Lett; 2019 Nov; 19(11):8333-8341. PubMed ID: 31657935
[TBL] [Abstract][Full Text] [Related]
9. Effects of Organic Acids on Drug Release From Ternary Polypeptide Nanoparticles Entrapping Carfilzomib.
Jackson S; Agbana P; Kim KB; Bae Y
J Pharm Sci; 2022 Apr; 111(4):1172-1177. PubMed ID: 34551351
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation.
Agbana P; Park JE; Rychahou P; Kim KB; Bae Y
J Pharm Sci; 2024 Mar; 113(3):711-717. PubMed ID: 37673172
[TBL] [Abstract][Full Text] [Related]
11. A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo.
Zhang C; Wang X; Cheng R; Zhong Z
Biomacromolecules; 2020 Jun; 21(6):2049-2059. PubMed ID: 32338875
[TBL] [Abstract][Full Text] [Related]
12. Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug.
Battogtokh G; Kang JH; Ko YT
Eur J Pharm Biopharm; 2015 Oct; 96():96-105. PubMed ID: 26212785
[TBL] [Abstract][Full Text] [Related]
13. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
[TBL] [Abstract][Full Text] [Related]
14. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.
Yang G; Gao M; Zhang Y; Kong Y; Gao L; Tao Y; Han Y; Wu H; Meng X; Xu H; Zhan F; Wu X; Shi J
Oncotarget; 2015 Sep; 6(29):26982-94. PubMed ID: 26323098
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid hydrophilic surface rehabilitating curcumin nanocrystals for targeted breast cancer treatment with prolonged biodistribution.
Ji P; Wang L; Chen Y; Wang S; Wu Z; Qi X
Biomater Sci; 2020 Jan; 8(1):462-472. PubMed ID: 31750450
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib in multiple myeloma.
Andreu-Vieyra C; Berenson JR
Expert Opin Biol Ther; 2014 Nov; 14(11):1685-99. PubMed ID: 25170966
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
[TBL] [Abstract][Full Text] [Related]
19. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
[TBL] [Abstract][Full Text] [Related]
20. Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells.
Federspiel JD; Codreanu SG; Goyal S; Albertolle ME; Lowe E; Teague J; Wong H; Guengerich FP; Liebler DC
Mol Cell Proteomics; 2016 Oct; 15(10):3233-3242. PubMed ID: 27503896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
